New research uncovering a vulnerability in prostate cancer cells could provide ways to improve treatments for prostate cancer. A major international study, led by scientists from Flinders University in Australia and South China University of Technology, revealed that two enzymes, PDIA1 and PDIA5, play a… Read More
The first challenge in drug discovery is selecting a biological target and validating it as a ‘druggable’ binding site. The key to this is identifying several potent compounds that can be used in more advanced validating assays. To achieve this go/no-go point, good chemical starting points need to be found… Read More
New research has identified chemical compounds that can precisely block the interaction between the major cancer-driving gene RAS and a key pathway for tumour growth. Researchers from the Francis Crick Institute and Vividion Therapeutics identified compounds that can block the RAS gene from mutating without preventing the… Read More
Unlock insights into ADC development with HUB Organoids’ factsheet on patient-derived organoids. Discover how advanced 3D tumour models are transforming preclinical testing and supporting safer, more effective antibody-drug conjugates. What you’ll learn: How organoids outperform traditional preclinical models for ADCs Strategies for evaluating efficacy, safety, and biomarker discovery Real-world case… Read More
News round-up for 29 September – 3 October by Bruno Quinney, Content Team at DDW. This week’s news is led by the agreement by Genmab to acquire Merus in a deal worth approximately $8 billion, an announcement which could have important ramifications in cancer research. Scientists have… Read More
Twelve leading research teams from around the world have been shortlisted for Cancer Grand Challenges’ fifth funding round, competing to win up to £20 million ($27 million) each to tackle cancer’s most formidable challenges. Launched in 2020 by Cancer Research UK and the US National Cancer Institute… Read More
Antibody-drug conjugates (ADCs) offer a targeted approach to cancer treatment, combining the specificity of antibodies with the potency of cytotoxic drugs, and have shown promise in improving patient outcomes. This eBook, sponsored by Abzena, explores the latest developments in the ADC field and the opportunities presented by next generation bioconjugates. Read More
In this free-to-attend, 25-minute, bite-sized webinar, hosted by DDW and supported by Revvity, Audrey Johnson, a scientist at Beantown Biotech, explores the innovative application of targeted protein degradation (TPD) in oncology research, with a specific focus on CDK2 degradation for potential cancer treatments. Johnson will be joined during the Q&A… Read More
Register now to secure your place at a new free-to-attend webinar on 23 September entitled ‘PROTAC-Mediated CDK2 degradation in oncology: Immunoassay tools for therapeutic discovery’, hosted by DDW and supported by Revvity. Audrey Johnson, a scientist at Beantown Biotech, explores the innovative application of targeted… Read More
Great Ormond Street Hospital Charity (GOSH Charity) has joined Cancer Research Horizons and LifeArc as a core partner to help drive innovation in children’s and young people’s cancer treatment, drug discovery consortium C-Further has announced. C-Further is an international consortium of drug discovery and development researchers, clinicians,… Read More
AecorBio has successfully completed an equity financing round of $1.5m (£1.1m), enabling the company to investigate its lead peptide candidate FT-002a to treat advanced prostate cancer. AecorBio, formerly known as HBC Immunology Inc, will use the financing to enable an Investigational New Drug (IND) application with the… Read More
A new study has revealed an important clue as to why immunotherapy fails in many patients with cancer. The study, led by researchers from the University of Birmingham supported by the National Institute for Health and Care Research (NIHR), Birmingham Biomedical Research Centre and the University of… Read More
The first patient has been dosed in a Phase IIa clinical trial testing the drug HTL0039732 to treat advanced solid tumours, Cancer Research UK and Nxera Pharma have announced. The patient was dosed with HTL0039732, a novel EP4 antagonist, in a Phase IIa clinical trial. This… Read More
Register now to secure your place at a new free-to-attend webinar on 23 September entitled ‘PROTAC-Mediated CDK2 degradation in oncology: Immunoassay tools for therapeutic discovery’, hosted by DDW and supported by Revvity. Audrey Johnson, a scientist at Beantown Biotech, explores the innovative application of targeted… Read More
CAR-T therapy could be an effective treatment for leukaemia, preclinical data published by biotechnology company Gyala Therapeutics suggests. The data emerged from a study highlighting the use of CAR-T therapy, GYA01, to treat acute myeloid leukaemia (AML) and T-cell acute lymphoblastic leukaemia (T-ALL). The study is the… Read More
Register now to secure your place at a new free-to-attend webinar on 23 September entitled ‘PROTAC-Mediated CDK2 degradation in oncology: Immunoassay tools for therapeutic discovery’, hosted by DDW and supported by Revvity. Audrey Johnson, a scientist at Beantown Biotech, explores the innovative application of targeted… Read More
